Rapport Therapeutics brought in $150 million in funds in a Series B round, the company announced Wednesday.

Investors include Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital as well as Johnson & Johnson Innovation, among others.

The Series B funding round comes six months after Rapport launched with $100 million in a Series A round. That effort was backed by Third Rock Ventures, ARCH Venture Partners and Johnson & Johnson Innovation.

Rapport is focused on developing small-molecule drugs that target neurological disorders, with its lead candidate currently being explored for drug-resistant seizure disorders.

In tandem with the Series B announcement, Rapport is also appointing two new members to its board of directors: Raymond Kelleher, who is currently managing director of Cormorant Asset Management and James Healy, managing partner of Sofinnova Investments.

“We are appreciative for the support of such a prominent group of new investors and excited to welcome Ray and Jim to our board of directors,” Rapport CEO Abraham Ceesay said in a statement.

Kelleher joins the Rapport board of directors after a long career as a neurologist. He currently serves as associate neurologist at Massachusetts General Hospital, where he’s worked for nearly 30 years. He’s also on the boards of several other pharma companies, including Arkuda Therapeutics, Expansion Therapeutics, Garuda Therapeutics and Chroma Therapeutics.

Kelleher pointed to Rapport’s “exciting period of growth” in a statement, adding that the company is “pursuing a unique approach that exploits novel molecular insights with the goal of targeting ion channel receptors with unprecedented precision.”

Healy, meanwhile, has spent 23 years at Sofinnova and serves on the boards of companies including ArriVent Biopharma, Atsena Therapeutics, Karuna Therapeutics, and others.

Ceesay added in a statement that Rapport is “poised for tremendous growth and look[s] forward to pursuing a wide variety of opportunities to serve patients who desperately need more effective treatments.”

“Rapport is extremely well positioned to advance our ongoing clinical programs in seizure and psychiatric disorders, and to expand our pipeline by harnessing our unique capability to leverage receptor-associated proteins for precision neuromedicine,” Ceesay continued.

For a January 2024 article about Goldman Sachs closing an $650M investment fund to spur life sciences innovation, click here.